The earnings call highlighted substantial growth in revenue and operational achievements, alongside successful yield enhancement and ASCENIV utilization. While there are some challenges with reimbursement and conservative guidance regarding yield enhancement revenue, the overall sentiment is largely positive due to strong financial results and strategic advancements.

Company Guidance -

Q3 2025

During ADMA Biologics' second quarter 2025 financial results call, the company provided a comprehensive update on its performance and future guidance. Key metrics highlighted include total revenues reaching $122 million, marking a 29% year-over-year growth after adjustments. Adjusted net income and adjusted EBITDA saw substantial increases of 85% and 59%, respectively. The company reaffirmed its guidance for 2025, anticipating $500 million or more in total revenue, with adjusted EBITDA of at least $235 million and adjusted net income of $175 million or more. Looking ahead to 2026, ADMA expects $625 million in total revenue, adjusted EBITDA of $340 million, and adjusted net income of at least $245 million. Operational advancements include an FDA-approved yield enhancement process that boosts bulk immunoglobulin production by 20%, expected to drive meaningful gross margin expansion starting in early 2026. The company also completed a $300 million debt refinancing, reducing borrowing costs and enhancing financial flexibility. Additionally, ADMA expanded its infrastructure with the acquisition of a new facility to support future growth, potentially increasing cGMP manufacturing space by up to 30%. The company remains focused on innovation and operational excellence to achieve its long-term growth target of $1.1 billion in annual revenue prior to 2030.

Record Revenue and Growth

Total revenue reached $122 million, up 14% year-over-year, or approximately 29% when adjusting for a nonrecurring Medicaid rebate accrual reversal. Adjusted net income and adjusted EBITDA grew approximately 85% and 59% year-over-year, respectively.

Yield Enhancement Success

Commercial scale production utilizing FDA-approved yield enhancement process is underway, achieving a 20% or greater increase in bulk IG output. This is expected to drive significant gross margin expansion.

ASCENIV Utilization

ASCENIV utilization reached record highs with expanded availability of high-titer plasma and strong forward demand indicators, indicating deepened market penetration and broadened patient access.

Debt Refinancing and Financial Flexibility

Completed a JPMorgan-led debt refinancing, reducing borrowing costs and enhancing liquidity with a new $300 million credit agreement.

Facility and Infrastructure Expansion

Acquisition of a facility and adjacent land near Boca Raton campus for expanded cold storage, warehousing, and potential manufacturing space increase by up to 30%.

ADMA Biologics (ADMA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ADMA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	0.15 / -	0.163	―	―	―
Aug 06, 2025	2025 (Q2)	0.14 / 0.15	0.142	3.52% (<+0.01)	―
May 07, 2025	2025 (Q1)	0.15 / 0.14	0.089	52.81% (+0.05)	―
Mar 03, 2025	2024 (Q4)	0.15 / 0.14	-0.08	276.25% (+0.22)	―
Nov 07, 2024	2024 (Q3)	0.13 / 0.16	0.01	1530.00% (+0.15)	―
Aug 08, 2024	2024 (Q2)	0.08 / 0.14	-0.018	888.89% (+0.16)	―
May 09, 2024	2024 (Q1)	0.06 / 0.09	-0.03	396.67% (+0.12)	―
Feb 28, 2024	2023 (Q4)	0.03 / -0.08	-0.06	-33.33% (-0.02)	―
Nov 08, 2023	2023 (Q3)	>-0.01 / 0.01	-0.08	112.50% (+0.09)	―
Aug 09, 2023	2023 (Q2)	-0.03 / -0.02	-0.07	74.29% (+0.05)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ADMA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$18.54	$16.75	-9.65%
May 07, 2025	$23.61	$21.20	-10.21%
Mar 03, 2025	$15.83	$17.01	+7.45%
Nov 07, 2024	$19.72	$22.62	+14.71%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does ADMA Biologics (ADMA) report earnings?

ADMA Biologics (ADMA) is schdueled to report earning on Nov 05, 2025, TBA (Confirmed).

What is ADMA Biologics (ADMA) earnings time?

ADMA Biologics (ADMA) earnings time is at Nov 05, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ADMA EPS forecast?

ADMA EPS forecast for the fiscal quarter 2025 (Q3) is 0.15.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing